Persistent Asset Partners’s Taysha Gene Therapies TSHA Stock Holding History

Persistent Asset Partners’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$909K	Buy	+133,411	New	+$789K	0.27%	69

Other funds holding TSHA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Persistent Asset Partners's TSHA Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 133,411 shares worth $909K. The stake represents 0.27% of the portfolio and ranks #69 among its holdings.

208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Persistent Asset Partners held 133,411 shares of Taysha Gene Therapies worth $909K as of Q2 2026.
Taysha Gene Therapies was a new Persistent Asset Partners position in Q2 2026.
Taysha Gene Therapies made up 0.27% of Persistent Asset Partners's portfolio in Q2 2026, its #69 holding.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.